Cosentyx is a medication that is used to treat various autoimmune diseases, including psoriasis, psoriatic arthritis, and ankylosing spondylitis. The active ingredient in Cosentyx is secukinumab, which works by blocking a protein called interleukin-17A that is involved in the inflammatory response [1].

According to a study published in the Journal of the European Academy of Dermatology and Venereology, Cosentyx has been shown to be effective and safe for elderly patients with psoriasis. The study included patients over the age of 65 and found that Cosentyx improved their psoriasis symptoms and quality of life [2].

Another study published in the Journal of Dermatological Treatment found that Cosentyx was effective and well-tolerated in elderly patients with psoriatic arthritis. The study included patients over the age of 65 and found that Cosentyx improved their joint symptoms and physical function [3].

However, it is important to note that as with any medication, there may be risks and side effects associated with Cosentyx. Patients should discuss the potential benefits and risks of the medication with their healthcare provider before starting treatment.

Overall, the available evidence suggests that Cosentyx can be effective and safe for elderly patients with psoriasis and psoriatic arthritis. However, as with any medication, individual results may vary and patients should discuss their specific situation with their healthcare provider.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] https://pubmed.ncbi.nlm.nih.gov/29404966/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5847154/